DON'T MISS OUT!
Phase 3 Clinical Trial For Alzheimer's Disease Underway Free Webinar to Learn More
Please Pass On This Exciting News!
To Register for the webinar click here
In an area where an effective disease-modifying therapy greatly needed, Professor Wischik is on the verge of becoming an overnight success — 30-plus years in the making — if the Phase III trials for LMTX®, the second-generation tau aggregation inhibitor (TAI), prove to be as successful as the Phase II trials of its predecessor, rember®.